A lyophilized pharmaceutical composition comprising: a) dalbavancin hydrochloride or its pharmaceutically acceptable salt b) a pharmaceutically acceptable amount of amino acid as stabilizer) the ratio of dalvabancin to stabilizer is 1:0.8 to 1:1 by weight, d) said formulation has a pH in the range of 5.1-6 v) said formulation contains no more than about 1% MAG by weight after 3 Months at 40°C and 75 % RH.